Association between soy and isoflavone consumption, gastrointestinal (GI) cancer risk
the ONA take:
According to a new study published in the European Journal of Nutrition, soy consumption is only associated with a small decrease in gastrointestinal cancer risk, while isoflavone consumption is significantly associated with a reduction in gastrointestinal cancer risk.
For the study, researchers sought to investigate the association between soy and isoflavone consumption and gastrointestinal cancer risk. Isoflavone is an active soy constituent but can be consumed as a dietary supplement.
Researchers identified 22 case-control and 18 cohort studies with a total participation of 633,476 patients and 13,639 cases of gastrointestinal cancer. Of the 40 studies, 10 were used for a subgroup analysis for isoflavone consumption.
Results showed that there was only a small reduction in gastrointestinal cancer risk due to soy intake (combined odds ratio = 0.93; 95% CI: 0.87 - 0.99; P = 0.01).
Particularly, the association was stronger for colon and colorectal cancers. In contrast, the subgroup analysis for isoflavone showed a significant reduction in gastrointestinal cancer risk, especially colorectal cancer risk, due to isoflavone consumption (OR = 0.73; 95% CI: 0.59 - 0.92; P = 0).
Soy consumption is only associated with a small decrease in gastrointestinal cancer risk.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|